# A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab

> **NCT06535737** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Chulalongkorn University** · enrollment: 40 (estimated)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT06535737
- **Lead sponsor:** Chulalongkorn University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08
- **Primary completion:** 2026-07
- **Final completion:** 2026-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06535737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06535737, "A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06535737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*